Green Cross Corporation
006280 | KO
Overview
Corporate Details
- ISIN(s):
- KR7006280002
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 이현로30번길 107(보정동), 용인시
- Website:
- https://www.gccorp.com/eng/index
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-22 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.2 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.2 MB | ||
| 2025-08-05 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 25.5 KB | ||
| 2025-08-01 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.0 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 4.2 MB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 3.2 MB | ||
| 2025-04-30 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.0 KB | ||
| 2025-04-08 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-08 00:00 |
Management Reports
[기재정정]장래사업ㆍ경영계획(공정공시)
|
Korean | 14.0 KB | ||
| 2025-03-31 00:00 |
Management Reports
[기재정정]장래사업ㆍ경영계획(공정공시)
|
Korean | 11.7 KB | ||
| 2025-03-27 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 50.2 KB | ||
| 2025-03-26 00:00 |
AGM Information
정기주주총회결과
|
Korean | 19.8 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
사업보고서 (2024.12)
|
Korean | 717.7 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 19.6 KB | ||
| 2025-03-13 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.8 KB |
Automate Your Workflow. Get a real-time feed of all Green Cross Corporation filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Green Cross Corporation
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Green Cross Corporation via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
South Korea
290650
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
United States of America
LPTX
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
United States of America
LEGN
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
United States of America
LENZ
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
United States of America
LXEO
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
United States of America
LXRX
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
Sweden
LIDDS
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
United States of America
LFCR
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
United States of America
LIMN
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Israel
LCTX